Reid Merryman, MD, on Pre- and Post-Transplant Data for Patients with DLBCL


Merryman explains the value of evaluating separate transplant-related questions for patients with relapsed or refractory diffuse large B-cell lymphoma.

Reid Merryman, MD, of the Dana-Farber Cancer Institute, spoke with CancerNetwork® about the significance of dividing cohorts of patients with diffuse large B-cell lymphoma (DLBCL) into by pre- and post-transplantation groups and the questions that need to be asked from an oral presentation at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition.


So, I think it’s kind of 2 different questions. Looking at samples before transplant, you’re asking, “could we use information that we have to determine if transplant is the right treatment approach for patients?” And [What’s] different from 5 or 10 years ago, I think [is that] we have novel treatments. The obvious one would be CAR [chimeric antigen receptor] T-cell therapies that could potentially be used with curative intent in this setting for patients who we think might do poorly with autologous stem cell transplant.

We’re asking a little bit of a different question for the serial samples after autologous stem cell transplant. In that setting, obviously, the patient has undergone transplantation. The question would be, “are there things that we could do in terms of maintenance or consolidation therapies that might improve outcomes for high-risk patients who are likely to relapse?”

Related Videos
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
Data highlight that patients who are in Black and poor majority areas are less likely to receive liver ablation or colorectal liver metastasis in surgical cancer care.
Findings highlight how systemic issues may impact disparities in outcomes following surgery for patients with cancer, according to Muhammad Talha Waheed, MD.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Related Content